GSK has agreed to sell a drug substance manufacturing site in Cork, Ireland, to Thermo Fisher Scientific. It will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment, and expand capacity to develop and manufacture complex active pharmaceutical ingredients. The site contains 270 cubic meters of reactor capacity, 10 production buildings, an R&D pilot plant and lab infrastructure to support process development, scale-up and physical characterization of APIs. It produces highly specialized APIs for treating diseases including childhood cancer, depression and Parkinson's, and Thermo Fisher will continue to produce APIs for GSK under a multi-year supply agreement. Thermo also plans to expand use of the site to develop and produce complex APIs for other customers.
“GSK sells drug substance manufacturing site in Ireland.“
Michel Lagarde, senior vice president and president of Pharma Services for Thermo Fisher Scientific, said: "The GSK Cork site will enhance our API offering by expanding our development and commercial capabilities to provide much-needed capacity for APIs currently in development. This transaction is another great example of our strategy to build on our strong foundation by adding capacity and capabilities to our pharma services offering through a combination of capital investments and M&A."